Stocktoria
Gain Therapeutics, Inc. GANX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2021-03-18
Gain Therapeutics, Inc. statistics & valuation
Market cap$74.6M
P / B4.0×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -40328.3% | -12688.1% | -8379.8% |
| Net margin | — | — | -40354.3% | -12555.1% | -8418.9% |
| FCF margin | — | — | — | — | -7551.7% |
| Return on assets | -88.4% | -168.4% | -119.7% | -73.0% | -35.6% |
| Return on equity | -108.6% | -278.1% | -177.0% | -93.2% | -39.9% |
| Debt / equity | 0.02× | 0.06× | 0.05× | 0.03× | 0.02× |
| Current ratio | 6.63 | 2.97 | 3.59 | 5.11 | 14.78 |
| Revenue growth | — | — | -60.6% | -15.1% | 471.3% |
Source: SEC EDGAR filings · CIK 0001819411 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.